ADME studies distribution, metabolism

Pharmacokinetic/ ADME (absorption, distribution, metabolism, elimination) studies including bioanalytical method development... 

More recently, partially as a result of increased research sophistication and observations made in ADME (Absorption, Distribution, Metabolism, and Excretion) studies, increased attention is being given to evaluating metabolites of APIs. An old example (not being pursued because of the lack of patent protection) is the metabolite... 

If animals or humans are exposed to pharmaceutical compounds, they will either elicit a pharmacodynamic effect, e.g., show a suppression of blood pressure, or reveal in analytical blood samples exposure levels of the compound. This kinetic information of the parent compound and its metabolites is an important contribution for the extrapolation of safety data from animal studies to humans. Species differ considerably in regard to their kinetic conditions as Cmax, Tmax, Area Under the Curve (AUC), im and ADME (Absorption, Distribution, Metabolism and Excretion). 

An oral ADME (absorption, distribution, metabolism, excretion, following oral administration of the pesticide) study may also be of utility in refining the risk assessment. If a default value for dermal absorption of 100 % is applicable based on the physico-chemical properties of a substance and an appropriate oral ADME study is available, the results of this study may be used to refine the default value for dermal absorption. It is required that the oral absorption is determined at low dose levels in experimental animals, in order to obtain an accurate estimate of the oral absorption. Based on theoretical grounds and supported by a comparison of oral and dermal absorption data available for twelve pesticides, it is assumed that dermal absorption will not exceed oral absorption (Hakkert et al unpublished data). 

Another type of study is described by the term ADME (absorption, distribution, metabolism, and elimination). The rate of absorption describes how fast the drug substance enters the bloodstream and is a measure of bioavailability. The distribution in the body is measured to confirm that the substance reaches the target organ and that it does not accumulate in other organs. Metabolism is the chemical conversion of the substance in the body to other compounds and elimination describes how fast and by which route the substance and its metabolites are eliminated from the body. 

Pharmacokinetic studies are often referred to using the acronym ADME - absorption, distribution, metabolism and excretion -reflecting the four main areas for study. The use of such an acronym is simplistic in nature when one considers that each of the four areas is interdependent on one or more of the others, but nevertheless it is a convenient way of dividing up the studies that fall under the broad heading of pharmacokinetics. 

Biotech and pharma companies outsource a number of different functions. In the discovery phase, the syntheses of building blocks, intermediates, and especially libraries are frequently outsourced, often to India or Eastern Europe. Offshoring of chemistry is frequent, that of biology less so. But ADME Absorption, Distribution, Metabolism, and Excretion) studies and animal models for preclinical development are now sometimes done in China, for example, at Shanghai s WuXi Pharmatech, whose customers currently include nearly all of big pharma and big biotech. ... 

A series of tetrahydropyrido[3,2-l ]azepin-6-ones with a trifluoromethyl group was prepared to study their ADME (absorption, distribution, metabolism, and excretion) profile (14ARK139). The pyridine ring was prepared by a traditional condensation followed by the formation of an oxime (Scheme 6). The key step includes a Beckmann ring expansion of this oxime. 

Various in vitro assays are widely available for profiling distribution, metabolism, and pharmacokinetics (DMPK, also referred to as ADME absorption, distribution, metabolism, and excretion). Such properties of molecules are measured to ultimately predict their in vivo behavior. The metabolic stability of molecules is assessed routinely in drug discovery units by way of medium- to high-through-put assays using hepatic microsomes or hepatocytes obtained from different species (usually rat and/or human). Permeability assays (e.g., utilizing Caco-2 or MDCK cells) together with an assessment of efflux potential are also useful to troubleshoot unexpectedly low cell activity or can help select candidates for subsequent in vivo studies. 

The partition coefficient and aqueous solubility are properties important for the study of the adsorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) of drugs. The prediction of the ADME-Tox properties of drug candidates has recently attracted much interest because these properties account for the failure of about 60 % of all drug candidates in the clinical phases. The prediction of these properties in an early phase of the drug development process could therefore lead to significant savings in research and development costs. 

From a methodological viewpoint, our results suggest that range and sensitivity are useful descriptors of property spaces and can parameterize the capacity of a given molecule to span broad conformational and property spaces. In other words, range and sensitivity appear as promising descriptors of the dynamic behavior of a molecule. Their application to other dynamic QSAR studies [in particular, absorphon, distribution, metabolism and excretion (ADME) behavior] is under investigahon. 

An important part of the optimization process of potential leads to candidates suitable for clinical trials is the detailed study of the absorption, distribution, metabolism and excretion (ADME) characteristics of the most promising compounds. Experience has learned that physico-chemical properties play a key role in drug metabolism and pharmacokinetics (DMPK) [1-3]. As an example, physicochemical properties relevant to oral absorption are described in Fig. 1.1. It is important to note that these properties are not independent, but closely related to each other. 

This chapter will review some of the important methods for carrying out in vivo absorption and bioavailability studies, as well as attempt to provide an overview of how the information may be used in the drug discovery process. The chapter is aimed at medicinal chemists and thus will focus on the use of animals in discovery phase absorption, distribution, metabolism, and excretion/pharmacokinetic (ADME/PK) studies, rather than the design of studies that are for regulatory submission, or part of a development safety package. 

For a drug to interact with a target, it has to be present in sufficient concentration in the fluid medium surrounding the cells with receptors. Pharmacokinetics (PK) is the study of the kinetics of absorption, distribution, metabolism, and excretion (ADME) of drugs. It analyzes the way the human body deals with a drug after it has been administered, and the transportation of the drug to the specihc site for drug-receptor interaction. For example, a person has a headache and takes an aspirin to abate the pain. How does the aspirin travel from our mouth to reach the site in the brain where the headache is and act to reduce the pain ... 

Pharmacodynamics (PD) is the study of interactions between drugs and the body while pharmacokinetics (PK) describes the absorption, distribution, metabolism, and excretion (ADME) of drugs by the body. 

To Study interactions between proteins and drugs, an available tool is the Drug Absorption, Distribution, Metabolism, and Excretion (ADME) Associated Protein Database (see Table 1.5). The database contains information about relevant proteins, functions, similarities, substrates and hgands, tissue distributions, and other features of targets. Eor the understanding of pharmacokinetic (PK) and pharmacodynamic (PD) features, some available resources are listed in Table 1.5. For example, the Pharmacokinetic and Pharmacodynamic Resources site provides links to relevant software, courses, textbooks, and journals (see Note 5). For quantitative structure-activity relationship (QSAR), the QSAR Datasets site collects data sets that are available in a structural format (see Table 1.5). 

From a DMPK perspective, a common goal is to be able to compare multiple compounds based on their absorption, distribution, metabolism and excretion (ADME) properties as well their preclinical PK properties [8, 12-22]. Therefore, lead optimization typically is performed as an iterative process that uses the DMPK data to select structural modifications that are then tested to see whether the DMPK properties of the series have been improved. This iterative process is shown schematically in Fig. 13.2. Clearly an important element for the successful lead optimization of a series of NCEs is the ability to perform the DMPK assays in a higher throughput manner. The focus of this chapter will be to discuss ways that mass spectrometry (MS), particularly HPLC-MS/MS can be used to support the early PK studies for NCEs in a higher throughput manner. 

---